Τι πρέπει να γνωρίζω

Μάθετε για τις χρήσεις των βλαστοκυττάρων

 

Ενημερωτικό Υλικό

Μάθετε για τις χρήσεις των βλαστοκυττάρων

 

Κλείστε ραντεβού εδώ

Ενημερωθείτε υπεύθυνα για τα βλαστοκύτταρα

baby

Biohellenika Group of Companies

Biohellenika, the leader in stem cells banking and stem cell research, is a group of companies and includes Biohellenika Biotechnology Company S.A. (founded at 2006 in Thessaloniki), Biohellenika Biotechnology Applications S.A. (2007 Athens), Dentostem S.A. (2007 Athens), Cyvio Biotechnology LTD (Cyprus 2009), Biohellenika SRL (Romania 2010) and Cellenika LTD (2010 Melbourne Australia).

Biohellenika affiliated companies include today Biohellenika Cyprus, Biohellenika Bulgaria, BioStem (FYROM) and BeoStem (Serbia).

Biohellenika scientific collaborations include today: National Research Foundation, National Center for Technology Development (EKETA), Aristotle University Thessaloniki (AUTh), University of Athens, Athens Academy Foundation for Medical and Biological Research (AAFMBR), Democritus University Alexandropolis, MDC research institute Berlin in Germany and Masha University in IRAN.

R&D projects under development include:

  • The use of “sleeping beauty” Transposon for potential stem cell assisted gene therapy. (MDC Berlin and HNRF)
  • The use of “sleeping beauty” Transposon for developing of human cell lines capable of producing therapeutic proteins (MDC Berlin and EKETA)
  • Cartilage Regeneration (Aristotle University department of nanotechnology)
  • Cardiac Regeneration (AAFMBR)
  • Wound healing (Masha University, Plastic Surgery Clinics Medical School AUTh and Kapodistrian University Athens)
  • Use of stem cell therapy for the treatment of idiopathic pulmonary fibrosis (Pulmonology Clinic Democritus University Alexandropolis)
  • Development of effective scaffolds for tissue regeneration (Aristotle University and EKETA)

Biohellenika is also supporting stem cell therapy applications and clinical trials aiming to the therapeutic use of stem cells

Including:

  • Idiopathic pulmonary fibrosis (Pulmonology Clinic Democritus University Alexandropolis)
  • Autism (Metropolitan Hospital Athens)
  • Cardiac insufficiency (Cardiosurgery Clinic Medical School AUTh).

Biohellenika patent portfolio today includes

1. Measurement of the oxidant antioxidant balance in liquids (07733812)EP

2. A system for the storage of biological materials in cryotubes with integrally attached segments for cryopreservation and thawing (20100100290)GR

3. Regeneration of dental pulp using adipose derived stem cells, peripheral blood stem cells platelets and fibrin glue (20100100582)GR

4. Method and system of collection of placenta blood that is enriched in haematopoetic and mesenchymal stem cells (20100100605)GR

5. Method for the preparation of mesenchymal stem cells from the entire length of cord blood (20100100609)GR

PUBLICATIONS FROM R&D DEPARTMENT

1. N. Tsagias, K. Kouzi-Koliakos, V. Karagiannis, D.H. Alamdari, G.Koliakos Time and temperature before processing influence the recovery of umbilical cord blood hematopoietic progenitors.Transfusion. 2007 Aug;47(8):1550-2. G. Koliakos, D. Alamdari, N. Tsagias, K. Kouzi-Koliakos, E. Michaloudi, V. Karagiannis

2. A novel high-yield volume-reduction method for the cryopreservation of UC blood units. Cytotherapy. 2007 Oct 4;:1-6 N. Tsagias, K. Kouzi-Koliakos, I. Koliakos, E. Kostidou, V. Karagiannis, A. Daniilidis and G. Koliakos

3. Addition of Adipose-Derived Stem Cells in Cord Blood Cultures Stimulates Their Pluripotent Differentiation Transplantation Proceedings 2009, Vol: 41, issue 10:4340-4344 N.Tsagias, Iro Koliakos, M. Lappa, V. Karagiannis, and G. G. Koliakos.

4. Placenta perfusion has hematopoietic and mesenchymal progenitor stem cell potential. Transfusion 2011. Ω 51, p: 976. Anastasiadis K, Antonitsis P, Argiriadou H, Koliakos G, Doumas A, Khayat A, Papakonstantinou C, Westaby S.Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion. J Transl Med. 2011 Jan 19;9:12

5 . N. Tsagias, I. Koliakos, V. Karagiannis, M. Eleftheriadou, G.G. Koliakos.Isolation of mesenchymal stem cells using the total length of umbilical cord for transplantation purposes. Transfusion Medicine 2011 Aug;21(4):253-61.

6. H. Ravari, D. Hamidi-Almadari, M. Salimifar, S. Bonakdaran, MR. Parizadeh, G.Koliakos Treatment of no-healing woods with autologous bone marrow cells, platelets, fibrin glue and collagen matrix. Cytotherapy. 2011 Jul;13(6):705-11.

7. Tzouvelekis, G. Koliakos, P. Ntolios, I. Baira, E. Bouros, A. Oikonomou, A. Zissimopoulos, G. Kolios, D. Kakagia, V. Paspaliaris, I. Kotsianidis, M. Froudarakis, D. Bouros Stem cell therapy for idiopathic pulmonary fibrosis: A protocol proposal. J of Translational Medicine 2011: 9;182. J Transl Med. 2011 Oct 21;9:182.

8. S. Petrakis, Tamas Raskó 2, Lajos Mátés 3, Zoltan Ivics 4, Zsuzsanna Izsvák Kokkona Kouzi-Koliakou 1, 5 and George Koliakos. Genetic modification of human embryonic kidney and adipose-derived stromal cells using a Gateway compatible transposon vector.Biotechnology Journal 2012 Jul;7(7):891-7.

9. K. Kodonas, C. Gogos, S. Papadimitriou, K. Kouzi-Koliakou, D.Tziafas.Experimental Formation of Dentin-like Structure in the Root Canal Implant Model Using Cryopreserved Swine Dental Pulp Progenitor Cells.J Endod. 2012 Jul;38(7):913-9. Epub 2012 Mar 28.

10. K. Anastasiadis, P. Antonitsis, A. Doumas, G. Koliakos, H. Argiriadou, C. Vaitsopoulou, P. Tossios, C. Papakonstantinou, S. Westaby Stem cell transplantation combined with long-term mechanical circulatory support enhances myocardial viability in end-stage ischemic cardiomyopathy. Inter J Cardiology 2012 Mar 22;155(3):e51-3.

11. V. Karathanasis, S.Petrakis, K.Topouridou, E. Koliakou, G. Koliakos , E. Demiri Intradermal injection of GFP-producing adipose stromal cellSpromotes survival of random-pattern skin flaps in rats. DOI 10.1007/s00238-013-0810-y, 2013

12. J Transl Med. 2013 Jul 15;11:171. doi: 10.1186/1479-5876-11-171.A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Tzouvelekis A1, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D,Antoniadis A, Froudarakis M, Kolios G, Bouros D.

13. Iran Red Crescent Med J. 2013 Mar;15(3):256-9. doi: 10.5812/ircmj.7975. Lateral Traumatic Esophago-Cutaneous fistula in a Child; Platelet-Rich Fibrin Glue Challenge. Joudi M, Hamidi Alamdari D, Hyradfar M, Rahimi HR, Saremi E, Fathi M, Shojaeian R, Koliakos G.

14. Cell Tissue Bank. 2014, 15(3):491-9. A simple method for the quantitation of the stem cells derived from human exfoliated deciduous teeth using a luminescent cell viability assay.Tsagias N, Koliakos KK, Spyridopoulos T, Pitiakoudis M, Koliakos E, Korpeti I, Koliakos G.

15. Histol Histopathol. 2014 Nov 3. [Epub ahead of print] Pluripotent stem cells isolated from umbilical cord form embryonic like bodies in a mesenchymal layer culture. Kouzi-Koliakos K, Karagiannis V, Tsikouras P, Koliakos GG.

16. Regenerated Nerve Defects with a Nerve Conduit Containing Dental Pulp Stem Cells in Pigs: An Immunohistochemical and Electrophysiological Evaluation.Spyridopoulos T, Lambropoulou M, Pagonopoulou O, Birbilis T, Tsaroucha AK, Kouzi-Koliakou K, Botaitis S, Deftereou TE, Gaitanidis A, Pitiakoudis M. J Reconstr Microsurg. 2015 Sep;31(7):516-26. doi: 10.1055/s-0035-1555751. Epub 2015 Jun 30.

17. Front Neurosci. 2015 Jul 14;9:247. doi: 10.3389/fnins.2015.00247. eCollection 2015. Stem cell models of polyglutamine diseases and their use in cell-based therapies. Siska EK, Koliakos G2, Petrakis S

19. Graefes Arch Clin Exp Ophthalmol. 2015 Jul;253(7):1121-35. doi: 10.1007/s00417-015-3042-y. Epub 2015 May 23.Mesenchymal stem cells improve healing of the cornea after alkali injury. Almaliotis D1, Koliakos G, Papakonstantinou E, Komnenou A, Thomas A, Petrakis S, Nakos I, Gounari E, Karampatakis V. 1Laboratory of Experimental Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

20. Gene Ther. 2014 Feb;21(2):158-67. doi: 10.1038/gt.2013.68. Epub 2013 Nov 28. Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53.Baliaka A, Zarogoulidis P, Domvri K, Hohenforst-Schmidt W, Sakkas A, Huang H, Le Pivert P, Koliakos G, Koliakou E, Kouzi-Koliakos K, Tsakiridis K, Chioti A, Siotou E, Cheva A, Zarogoulidis K, Sakkas L

21. Iran Red Crescent Med J. 2013 Mar;15(3):256-9. doi: 10.5812/ircmj.7975. Epub 2013 Lateral Traumatic Esophago-Cutaneous fistula in a Child; Platelet-Rich Fibrin Glue Challenge. Joudi M1, Hamidi Alamdari D, Hyradfar M, Rahimi HR, Saremi E, Fathi M, Shojaeian R, Koliakos G.

22. Diagn Pathol. 2014 Nov 14;9:195. doi: 10.1186/s13000-014-0195-7. A gene therapy induced emphysema model and the protective role of stem cells. Zarogoulidis P, Hohenforst-Schmidt W, Huang H, Sahpatzidou D, Freitag L, Sakkas L, Rapti A7, Kioumis I, Pitsi, Kouzi-Koliakos K, Papamichail A, Papaiwannou A, Tsiouda T, Tsakiridis K, Porpodis K, Lampaki S, Organtzis J, Gschwendtner A, Zarogoulidis.


Three PhD thesis were supported by Biohellenika and five more are in progress

Biohellenika established a state of the art stem cell bank that includes two laboratories and storage facilities one in Thessaloniki and one in Athens (HNRF). Today Biohellenika stem cell bank is one of the most prominent stem cell banks in Greece, with a more than 50% market share. (In Greece today operate 10 family stem cell banks). Biohellenika is one of the three largest stem cell banks in Europe with an inventory of more than 20.000 collected units, and is the only stem cell bank in Greece that has successfully released units to a USA Hematology Clinic for autologous therapeutic use. Biohellenika has successfully supported up to date more than 340 autologous therapies in Greece and abroad.

Biohellenika has developed its own proprietary technology for stem cell banking that includes stem cell banking from the umbilical cord, Wharton’s jelly and placenta upon birth, dental pulp and ligaments, bone marrow and adipose tissue.

Biohellenika’s integrated quality system is based on AABB and FACT requirements as well as ISO 9001, ISO15189, ISO 13485, ISO14644, & ISO 27001. The quality system includes a customized CRM and Barcode information technology system and is fully computerized. Biohellenika’s laboratories and stem cell banking facilities meet all necessary requirements defined by the EU Commission Directive 2006/17/EC and rank among the best three laboratories in Europe.

Biohellenika is accredited by the American Association of Blood Banks (AABB) (September 2010). Biohellenika is also accredited according to ISO 15189:2007 by the Hellenic National Accreditation System with the document No 410, 8/2/2008.

Biohellenika has also certified its innovative storage system as a medical device according to ISO 13485.

Clean room operation is certified according to ISO 14644.

Biohellenika is certified according to the International Quality Management Systems Standard ISO 9001:2000 for the processing, qualitative controls and preservation of autologous cell systems (haematopoietic autografts from the umbilical blood and placenta; and mesenchymal autografts from the pulp of deciduous teeth and third molars; adipose tissue and wharton jelly), from the Lloyds Register Quality Assurance International Accreditation Group.

Biohellenika is in the process to be certified according to ISO 27001 for the information security.

Τhe laboratories of Biohellenika fully operate 24 hours a day, 7 days a week, 365 days a year and provide standard conditions of stem cell processing and storage. The central laboratories, total area of 2.700m², lie at the headquarters of the company, 65 Georgikis Scholis Avenue, at the exit of Thessaloniki to the airport, in the professional use building ZEDA. The Athens laboratories (TAK EIE) are situated in an independent building (800 m²) at walking distance from the HNRF main building. A storage facility is situated in the main HNRF building.

The laboratories of Biohellenika are supported by electric power generators, stabilizer of voltage, camera-observation system and 24 hours of clean room air microparticle density and liquid nitrogen tank temperature and level recording. Quality control laboratories of Biohellenika are fully equipped so all the required tests including microbiology, virology, and flow cytometry are performed in the company.

Our Laboratories

-

Stem Cells

-

Biohellenika TV

-

Biohellenika Procedure

-

Our Brochures

-

Stem Cells Bank Biohellenika - Web design Hexabit - W3C - Pagespeed - ACheckernoodles